Literature DB >> 12512923

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.

Nina Cavalli-Björkman1, Eva Osby, Jeanette Lundin, Mats Kalin, Anders Osterborg, Astrid Gruber.   

Abstract

Alemtuzumab (Campath-1H) is a humanized CD52 monoclonal antibody that targets normal as well as malignant B- and T-lymphocytes. Alemtuzumab has significant antitumor activity in chronic lymphocytic leukemia (B-CLL) but also induces immunosuppression. We describe a case of fatal adenovirus infection in a heavily pretreated patient with fludarabine-refractory B-CLL receiving alemtuzumab therapy, drawing attention to the fact that also viruses other than cytomegalovirus (CMV) and herpes simplex (HSV) need to be considered in B-CLL patients with fever of unknown origin while on alemtuzumab treatment.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12512923     DOI： 10.1385/MO:19:4:277

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  21 in total

1.  Adenovirus infection in pediatric liver transplant recipients.

Authors:  M G Michaels; M Green; E R Wald; T E Starzl
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

2.  Adenovirus infections in hematopoietic stem cell transplant recipients.

Authors:  D S Howard; G L Phillips II; D E Reece; R K Munn; J Henslee-Downey; M Pittard; M Barker; C Pomeroy
Journal:  Clin Infect Dis       Date:  1999-12       Impact factor: 9.079

3.  Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children.

Authors:  F Legrand; D Berrebi; N Houhou; F Freymuth; A Faye; M Duval; J F Mougenot; M Peuchmaur; E Vilmer
Journal:  Bone Marrow Transplant       Date:  2001-03       Impact factor: 5.483

4.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Authors:  Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

Review 5.  Community respiratory virus infections following lung transplantation.

Authors:  J L Billings; M I Hertz; C H Wendt
Journal:  Transpl Infect Dis       Date:  2001-09       Impact factor: 2.228

6.  High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

Authors:  C E Dearden; E Matutes; B Cazin; G E Tjønnfjord; A Parreira; B Nomdedeu; P Leoni; F J Clark; D Radia; S M Rassam; T Roques; N Ketterer; V Brito-Babapulle; M J Dyer; D Catovsky
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Fatal disseminated adenoviral infection in a renal transplant patient.

Authors:  H Ardehali; K Volmar; C Roberts; M Forman; L C Becker
Journal:  Transplantation       Date:  2001-04-15       Impact factor: 4.939

8.  Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

Authors:  Jeanette Lundin; Eva Kimby; Magnus Björkholm; Per-Anders Broliden; Fredrik Celsing; Viktoria Hjalmar; Lars Möllgård; Peppy Rebello; Geoff Hale; Herman Waldmann; Håkan Mellstedt; Anders Osterborg
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 9.  Adenoviruses in the immunocompromised host.

Authors:  J C Hierholzer
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

10.  Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia.

Authors:  A Osterborg; A S Fassas; A Anagnostopoulos; M J Dyer; D Catovsky; H Mellstedt
Journal:  Br J Haematol       Date:  1996-04       Impact factor: 6.998
View more
  8 in total

Review 1.  Infectious complications associated with monoclonal antibodies and related small molecules.

Authors:  Edsel Maurice T Salvana; Robert A Salata
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

2.  Disseminated adenovirus infection in cancer patients presenting with focal pulmonary consolidation.

Authors:  Yeon Joo Lee; Paola Palomino-Guilen; N Esther Babady; Daryl M Lamson; Kirsten St George; Yi-Wei Tang; Genovefa A Papanicolaou
Journal:  J Clin Microbiol       Date:  2013-10-16       Impact factor: 5.948

Review 3.  Treatment of adenovirus infections in the immunocompromised host.

Authors:  P Ljungman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-10       Impact factor: 3.267

4.  Development of an Antigen Detection ELISA for Bancroftian Filariasis Using BmSXP-Specific Recombinant Monoclonal Antibody.

Authors:  Anizah Rahumatullah; Theam Soon Lim; Muhammad Hafiznur Yunus; Rahmah Noordin
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 3.707

5.  Adenovirus diseases: a systematic review and meta-analysis of 228 case reports.

Authors:  Jie Gu; Qing-Qing Su; Ting-Ting Zuo; Yan-Bin Chen
Journal:  Infection       Date:  2020-07-27       Impact factor: 7.455

6.  A compact phage display human scFv library for selection of antibodies to a wide variety of antigens.

Authors:  Potjamas Pansri; Nanthnit Jaruseranee; Kuntalee Rangnoi; Peter Kristensen; Montarop Yamabhai
Journal:  BMC Biotechnol       Date:  2009-01-29       Impact factor: 2.563

7.  Diagnostic Potential of Recombinant scFv Antibodies Generated Against Hemagglutinin Protein of Influenza A Virus.

Authors:  Roopali Rajput; Gaurav Sharma; Varsha Rawat; Anju Gautam; Binod Kumar; B Pattnaik; H K Pradhan; Madhu Khanna
Journal:  Front Immunol       Date:  2015-09-02       Impact factor: 7.561

8.  Isolation of recombinant antibodies directed against surface proteins of Clostridium difficile.

Authors:  Ali Nazari Shirvan; Robert Aitken
Journal:  Braz J Microbiol       Date:  2016-03-02       Impact factor: 2.476
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.